Stock DNA
Pharmaceuticals & Biotechnology
PLN 5,911 Million (Mid Cap)
22.00
NA
0.00%
1.21
-999,999.00%
9.78
Revenue and Profits:
Net Sales:
671 Million
(Quarterly Results - Mar 2026)
Net Profit:
86 Million
Total Returns (Price + Dividend) 
Company does not have enough history
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.90%
EBIT Growth (5y)
-13.71%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
59.03%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
22
Industry P/E
Price to Book Value
9.78
EV to EBIT
17.41
EV to EBITDA
11.20
EV to Capital Employed
4.98
EV to Sales
2.67
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
28.59%
ROE (Latest)
45.18%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
670.90
618.30
8.51%
Operating Profit (PBDIT) excl Other Income
169.70
123.70
37.19%
Interest
16.90
18.50
-8.65%
Exceptional Items
0.00
-0.20
100.00%
Consolidate Net Profit
85.90
39.30
118.58%
Operating Profit Margin (Excl OI)
168.60%
114.20%
5.44%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 8.51% vs 0.98% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 118.58% vs -51.30% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,410.50
1,950.10
23.61%
Operating Profit (PBDIT) excl Other Income
580.90
481.00
20.77%
Interest
68.10
56.30
20.96%
Exceptional Items
-6.70
14.00
-147.86%
Consolidate Net Profit
261.90
232.00
12.89%
Operating Profit Margin (Excl OI)
157.30%
163.80%
-0.65%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 23.61% vs 22.80% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 12.89% vs 78.46% in Dec 2024






